Please assess the completion status of the following clinical trial:

Trial Title: Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female participants (outpatients) between the regional age of majority (18 or 19 years of age) to 65 years of age, inclusive, at the time of informed consent.~* Primary diagnosis of MDD and in a current non-psychotic major depressive episode (MDE) as defined by Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria, who have been outpatients for at least 4 weeks, and have an inadequate response, per investigator judgment, to 1 or 2 adequate treatments of ADTs in their current MDE, including current ADT.~* Participants with a Patient Health Questionnaire 9-item scale (PHQ-9) ≥ 15 at the screening and baseline visits, if separate.~Exclusion Criteria:~* Participants currently or previously treated with brexpiprazole including participants who received brexpiprazole in any prior clinical trial.~* Participants with a concurrent DSM-5 diagnosis of the following will be excluded:~  * Schizophrenia or schizoaffective disorder~ * Bipolar I or bipolar II disorder~ * Post-traumatic stress disorder~ * Dementia~ * Eating disorder~ * Borderline personality disorder~ * Antisocial personality disorder~* Participants with a suicidality score of 3 based on Inventory of Depressive Symptomatology Self-Report (IDS-SR) suicidality item 18 or participants who, in the opinion of the investigator, presents a serious risk of suicide.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Brexpiprazole (Type: OTHER): Participants received brexpiprazole as a flexible dose; 0.5 mg to 2 mg, orally (PO), QD, and continued on the stable dose of ADT up to 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).